AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; scalable automated pharmacy dispensing equipment; medication and supply dispensing cabinets; and packaging solutions to institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physician practices in various disease states, such as oncology, as well as to other healthcare providers, including dialysis clinics; distributes plasma and other blood products, injectible pharmaceuticals, and vaccines; and third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company's Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; and specialty transportation and logistics services for the biopharmaceutical industry. AmerisourceBergen Corporation markets its products and services through independent sales forces and marketing organizations. The company was founded in 1985 and is based in Chesterbrook, Pennsylvania.
ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
ACI Worldwide, Inc. develops, markets, installs, and supports software products and services for facilitating electronic payments worldwide. The company offers products and services covering various domains, including online banking and cash management that manages payments and cash flows through the online or mobile channel; managing and processing monetary, non monetary, sales, and account origination financial transactions; and managing trade related transaction types. The company's products also cover various domains within the payments and banking marketplace, such as community financial services, including online and mobile banking and payment systems, and security solutions; software to support in house issuance of payment instruments and management of a consumer payment from transaction acquiring to settlement; wholesale banking payments that manage corporate payments and messages through their lifecycle; and merchant retail, which manages a consumer payment within a merchant retailer and supporting services. In addition, its products cover payment fraud management, which secures payments against fraud and money laundering; and payment infrastructure to operate and optimize the payments system. Further, the company offers bill presentment and payment collection services to tax authorities, higher education, utilities, and health care providers, as well as provides implementation, product support, technical, educational, testing, expert consultancy, and facilities management services. ACI Worldwide, Inc. sells its products under the ACI Worldwide and ACI Payment Systems brands. It serves financial institutions, including national, regional, and global banks, as well as community banks and credit unions; e-payment processors; retailers; and billers. The company was formerly known as Transaction Systems Architects, Inc. and changed its name to ACI Worldwide, Inc. in July 2007. ACI Worldwide, Inc. was founded in 1993 and is headquartered in Naples, Florida.
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company's products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications. The company was founded in 1995 and is headquartered in Ardsley, New York.
Actua Corporation operates as a multi-vertical cloud technology company that creates value for customers and provides transformative efficiency to vertical markets worldwide. It provides Bolt Platform, a cloud-based platform that allows captive and independent insurance agents to meet various commercial and personal property, and casualty insurance needs of their customers; and cloud-based digital communication management platform, which enables government organizations to provide citizens with access to new information, delivering updates through e-mail, mobile text alerts, RSS, and social media channels from government entities at the national, state, and local levels. The company also offers an integrated suite of cloud-based solutions that help companies manage various environmental, health, and safety regulatory compliance requirements worldwide. In addition, it provides a cloud-based publishing platform that allows manufacturers and retailers to share their products in a connected, contextual way among Facebook users; operates a cloud-based healthcare payments network focused exclusively on healthcare providers, payers, and patients; and offers a cloud-based transcript exchange and intelligence platform that enables the exchange of electronic transcripts and other student records among schools, universities, state education agencies, and individuals. The company was formerly known as ICG Group, Inc. and changed its name to Actua Corporation in September 2014. Actua Corporation was founded in 1996 and is headquartered in Radnor, Pennsylvania.
Allegion plc is a global provider of security products and solutions. The Company offers a portfolio of mechanical and electronic security products across a range of brands. The Company operates in three geographic regions: Americas; Europe, Middle East, India and Africa (EMEIA), and Asia Pacific. As of November 15, 2013, the Company was selling its security products and solutions under 23 brands in 120 countries, including Schlage, Von Duprin, LCN, CISA and Interflex. It sell a range of security products and solutions for end-users in commercial, institutional and residential facilities worldwide, including into the education, healthcare, government, commercial office and single- and multi-family residential markets. As of November 15, 2013, it operated 18 production facilities, including nine in the Americas region, seven in EMEIA and two in Asia Pacific.
AMAG Pharmaceuticals, Inc. develops and commercializes specialty pharmaceutical products. The company markets Feraheme (ferumoxytol) injection for use as an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It markets Feraheme in the United States and Canada; and as Rienso in the European Union. The company sells Feraheme to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as an IV iron replacement therapeutic agent in China. The company was founded in 1981 and is based in Waltham, Massachusetts.
American Tower Corporation is a real estate investment trust. It invests in the real estate markets across the globe. The firm through its subsidiaries owns, operates and develops wireless and broadcast communications real estate. Through its subsidiaries it leases antenna space on multi-tenant communications sites to wireless service providers, radio and television broadcast companies, wireless data providers, government agencies and municipalities and tenants in a number of other industries. American Tower Corporation was founded in 1995 and is headquartered in Boston, Massachusetts.
Alpha Natural Resources, Inc., together with its subsidiaries, is engaged in extracting, processing, and marketing thermal and metallurgical coal in Virginia, West Virginia, Kentucky, Pennsylvania, and Wyoming. As of December 31, 2013, the company operated 81 mines and 25 coal preparation plants in Northern and Central Appalachia and the Powder River Basin with approximately 4.3 billion tons of proven and probable coal reserves. The company also repairs and resells equipment and parts used in surface mining and supporting preparation plant operations; manufactures patented particulate scrubbers and filters for underground diesel engine applications; and rebuilds underground mining equipment. In addition, it owns and operates third-party end-user coal handling facilities; purchases and sells third party coal; sells non-strategic assets, such as timber, gas, and oil rights; leases and sells non-strategic surface properties and reserves; and provides coal and environmental analysis services. The company serves electric utilities, steel and coke producers, industrial customers, and energy traders and brokers. Alpha Natural Resources, Inc. was founded in 2002 and is based in Bristol, Virginia.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates through four segments: Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy. The Merchant Gases segment sells atmospheric gases, such as oxygen, nitrogen, and argon; process gases comprising hydrogen and helium and carbon dioxide; and medical and specialty gases for the metal, glass, chemical processing, food processing, healthcare, steel, general manufacturing, and petroleum and natural gas industries. The Tonnage Gases segment offers hydrogen, carbon monoxide, nitrogen, oxygen, and syngas to the energy production and refining, chemical, and metallurgical industries. The Electronics and Performance Materials segment provides nitrogen trifluoride, silane, arsine, phosphine, white ammonia, silicon tetrafluoride, carbon tetrafluoride, hexafluoromethane, critical etch gases, and tungsten hexafluoride; and tonnage gases, chemicals mechanical planarization slurries, specialty chemicals, and services and equipment for the manufacture of silicon and compound semiconductors, and thin film transistor liquid crystal displays. This segment also offers performance materials for a range of products, including coatings, inks, adhesives, civil engineering, personal care, institutional and industrial cleaning, mining, oil refining, and polyurethanes. The Equipment and Energy segment designs and manufactures cryogenic equipment for air separation, hydrocarbon recovery and purification, natural gas liquefaction, and helium distribution; and provides plant design, engineering, procurement, and construction management services for the chemical and petrochemical manufacturing, oil and gas recovery and processing, and steel and primary metals processing industries. Air Products and Chemicals, Inc. was founded in 1940 and is headquartered in Allentown, Pennsylvania.